Systematic review on rapidity of onset of action for interleukin‐17 and interleukin‐23 inhibitors for psoriasis

Several novel biologics are available or in development for moderate‐to‐severe plaque psoriasis. These drugs may differ in time until Psoriasis Area and Severity Index ( PASI ) response is obtained. In this systematic review, we examined the time to onset of action for interleukin ( IL )‐17 and IL ‐23 agents in the treatment of psoriasis. The primary objective was the weighted mean time needed for 25% and 50% of patients with psoriasis to...